Sanuwave Health lowered its Q2 revenue guidance to $8.5–$9.5 million, undercutting its May forecast, due to reversed capital equipment market conditions for Ultramist. Strong consumables demand keeps applicator shipments on pace for a record quarterly volume despite CMS reimbursement clawbacks and secondary market cannibalization.
In Q2 2026, Sanuwave Health now expects revenue of $8.5 to $9.5 million, down from its initial May forecast, reflecting slower-than-anticipated capital equipment sales for the Ultramist system after early signs of market recovery in March and April were reversed in May and June.
Clawbacks of CMS reimbursement for skin substitute and allograft usage have led to wound care provider closures, fueling a secondary market for used Ultramist systems that has cannibalized demand for new capital equipment placements.
Despite headwinds in capital system sales, applicator consumables shipments are on pace for a record quarterly volume in Q2, driven by robust treatment demand and the company's efforts to train and support new users.
